NAD+ Therapy: What It Is, What the Evidence Shows, and Who Should Try It (2026)

Executive Summary

NAD+ (nicotinamide adenine dinucleotide) sits at the center of nearly every biological process that matters for healthy aging: cellular energy production, DNA damage repair, sirtuin longevity pathway activation, and neuroprotection. And one of the most well-documented facts in longevity biology is that NAD+ levels decline approximately 50% between ages 40 and 60.

That decline has measurable consequences. Lower cellular NAD+ means reduced mitochondrial efficiency, slower DNA repair, impaired sirtuin signaling, and a range of downstream effects that show up as fatigue, cognitive fog, slower recovery, and accelerating metabolic dysfunction. NAD+ therapy attempts to reverse this decline by restoring cellular NAD+ levels through supplementation or direct infusion. This guide explains what NAD+ therapy actually is, what the human evidence shows for each delivery method, who responds best, and how to access quality supervised protocols. For the broader picture of how NAD+ fits into a longevity peptide stack, see our anti-aging peptide therapy guide and our NAD+ and TRT guide.

At-a-Glance Comparison

NAD+ delivery method comparison as of 2026. Evidence grade reflects quality and independence of human data. Costs are typical US ranges; actual pricing varies by clinic and protocol.

Why NAD+ Declines and Why It Matters

Understanding why NAD+ levels fall with age — and what that decline actually affects — is the foundation for evaluating whether NAD+ therapy makes sense for you. Buyers searching for nad+ therapy usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

NAD+ is a coenzyme found in every cell in the body. It functions primarily as an electron carrier in the mitochondrial energy production chain (converting nutrients to ATP) and as a substrate for enzymes that regulate DNA repair (PARPs), longevity signaling (sirtuins), and inflammatory response (CD38). The problem: NAD+ synthesis declines with age for multiple reasons simultaneously. CD38 activity — an enzyme that degrades NAD+ — increases with age and chronic inflammation. NAD+ precursor availability decreases. And the energy demands on cells increase as mitochondrial efficiency declines, consuming NAD+ faster. The result is a progressive NAD+ deficit that research connects to mitochondrial dysfunction, accumulated DNA damage, reduced sirtuin activity (which regulates gene expression and cellular stress responses), and the slower metabolic function characteristic of biological aging. This is why NAD+ restoration has attracted serious longevity science attention — it's not targeting one specific pathway but rather a foundational coenzyme that multiple critical biological processes depend on. For the broader context of how NAD+ fits alongside other longevity interventions, see our anti-aging peptide therapy guide. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: assuming that restoring NAD+ levels automatically translates to dramatic lifespan extension — the mechanism is legitimate and the metabolic improvements are well-documented, but dramatic longevity outcome claims in humans remain ahead of the current evidence base. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

IV NAD+ Infusions: Fastest Delivery, Strongest Subjective Response

Intravenous NAD+ delivers the coenzyme directly into the bloodstream at therapeutic doses — producing faster, more pronounced cellular response than oral approaches and the strongest subjective effects per session. Buyers searching for nad+ therapy usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

IV NAD+ infusion bypasses all the absorption bottlenecks of oral supplementation — gut absorption variability, precursor conversion steps, first-pass metabolism. The NAD+ enters the bloodstream directly and becomes available for cellular uptake within minutes. Clinical protocols typically range from 250mg to 1,000mg per session, delivered over 1–3 hours (longer infusion times reduce the side effect profile). Most men report notable effects during and after infusion: a surge in mental clarity and energy that many describe as distinct from caffeine or stimulants — more of a baseline 'unlocking' than a stimulant peak. Published human data confirms rapid, measurable increases in whole-blood NAD+ concentrations. The practical downside is cost and access. High-quality IV NAD+ sessions run $200–$500 each, and most protocol designs include 4–10 sessions in the initial series followed by maintenance infusions every 4–8 weeks. Clinics that combine NAD+ with other longevity infusions (glutathione, vitamin C megadoses) are common — evaluate those additions separately on their own evidence merits. For current provider pricing and clinic comparisons, see our best NAD+ IV therapy providers guide. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: getting IV NAD+ without establishing testosterone and basic metabolic health first — NAD+ supports those systems but doesn't substitute for optimizing the foundational hormonal baseline. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

NMN vs NR: The Oral Supplementation Decision

NMN and NR are the two dominant oral NAD+ precursors — each with meaningful human clinical data and a slightly different metabolic pathway to cellular NAD+ restoration. Buyers searching for nad+ therapy usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Both NMN and NR are NAD+ precursors — they're one or two metabolic steps upstream of NAD+ in the biosynthesis pathway. The debate about which is 'better' has generated considerable research energy and considerable marketing noise. What the evidence actually shows: both reliably raise cellular NAD+ in humans at appropriate doses; head-to-head comparisons show some NMN advantages in direct cellular uptake via the recently identified NMN transporter (Slc12a8), but the practical difference in outcomes at matched doses is modest in current human trials. NMN has attracted more recent academic interest — David Sinclair's lab has published extensively on its effects in animal models and early human work, and the Keio University trial (250mg/day, older men) showed measurable improvements in muscle function and NAD+ levels. NR has the older and arguably larger body of independent human safety and efficacy data — Elysium Health's Basis and ChromaDex's TruNiagen have funded multiple independent academic trials. For practical purposes: NMN tends to command a premium price based on the Sinclair lab publicity; NR offers comparable cellular NAD+ elevation with a longer independent safety track record and lower typical cost. If budget matters, starting with NR is rational. If you want the most-researched precursor by recent publication count, NMN is the choice. Both should be taken with food; doses of 250–500mg/day are the best-studied ranges for most men. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: paying a significant premium for brand-name NMN on the basis of animal study marketing without accounting for the NR evidence base — both work; the practical outcome difference in humans at equivalent doses is modest. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

NAD+ and Testosterone: The Longevity Stack Intersection

NAD+ and testosterone share overlapping biological pathways — and men on TRT are among those who respond most clearly to adding NAD+ repletion as a complementary intervention. Buyers searching for nad+ therapy usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

The intersection of NAD+ and testosterone is both metabolic and practical. On the metabolic side: sirtuins activated by NAD+ — particularly SIRT1 — influence steroidogenesis and Leydig cell function. Animal research shows NAD+ repletion supports testosterone production pathways. In men on TRT, NAD+ addresses a different biological axis (cellular energy and DNA repair vs. direct androgenic signaling) with additive rather than overlapping effects. On the practical side: men in the TRT demographic — typically 35–60, experiencing fatigue, slower recovery, metabolic slowdown — are also the group where age-related NAD+ decline is most pronounced and most impactful. The fatigue that doesn't fully resolve on TRT alone is often in part a mitochondrial energy deficit that NAD+ addresses. This is why pairing NAD+ supplementation or IV protocols with TRT is so common at longevity-focused telehealth clinics. For the detailed overlap between NAD+ and TRT optimization, including which symptoms respond best to each and in what sequence, see our NAD+ and TRT complete guide. For TRT background and protocol design, see our TRT complete guide. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: adding NAD+ therapy before optimizing testosterone when low T is the primary driver of fatigue — testosterone optimization should come first; NAD+ is a powerful complement, not a substitute for addressing hormonal deficiency. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Who Responds Best to NAD+ Therapy

NAD+ therapy produces its most pronounced effects in specific profiles — understanding who responds best helps set realistic expectations. Buyers searching for nad+ therapy usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

The strongest responders to NAD+ therapy tend to cluster in predictable profiles. Men over 45 with documented fatigue and slow recovery: the combination of testosterone decline and NAD+ decline creates a compound energy deficit; addressing both is often dramatically more effective than either alone. Men with metabolic syndrome, insulin resistance, or elevated inflammatory markers: these conditions accelerate NAD+ consumption (via CD38 upregulation), so the deficit is often greater and the response to repletion more pronounced. Men experiencing cognitive sluggishness or 'brain fog': NAD+ supports neuronal energy metabolism and SIRT1-mediated neuroprotection; subjective cognitive improvements are among the most consistently reported outcomes in clinical experience. Men recovering from or managing chronic illness: conditions that drive systemic inflammation accelerate NAD+ depletion; repletion supports both energy and the DNA repair processes that chronic illness stresses. Conversely, younger men (under 35) with no documented metabolic issues typically see more modest subjective responses — their baseline NAD+ levels are less depleted. That doesn't mean there's no benefit, but the effect size tends to be smaller. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: expecting the same dramatic response at 35 as at 55 — the magnitude of benefit scales significantly with the degree of age-related NAD+ depletion. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

What NAD+ Therapy Actually Costs in 2026

NAD+ therapy costs range widely depending on delivery method and clinic — understanding the full cost picture helps you design a sustainable protocol. Buyers searching for nad+ therapy usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Cost is a significant practical consideration for NAD+ therapy, particularly IV protocols. Current 2026 US pricing: IV NAD+ infusions typically run $200–$500 per session at quality longevity clinics. A standard loading series of 4–6 sessions costs $800–$3,000. Maintenance infusions at 1x/month run $150–$350/session at most clinics offering package pricing. NMN supplements (250–500mg/day) run $50–$120/month depending on brand and dose — brands like Wonderfeel, DoNotAge, and ProHealth NMN are commonly cited in longevity communities. NR supplements (250–500mg/day) run $40–$100/month — TruNiagen and Elysium Basis are the most studied branded options. A practical protocol for most men: start with oral NMN or NR for 3 months ($50–$120/month) to assess response and establish baseline benefit. If significant energy and metabolic improvements are clear, continue oral maintenance. If you want to evaluate whether IV protocols produce meaningfully greater response, try a 2–3 session mini-series at a quality clinic and compare subjective outcomes. Many men find that oral NMN/NR supplementation captures 60–70% of the benefit at 15–20% of the cost of regular IV protocols — especially once they're beyond the loading phase. For current provider pricing and clinic comparisons, see our best NAD+ IV therapy providers guide and our NAD+ IV therapy cost guide. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: committing to an expensive monthly IV protocol without first trialing oral supplementation — most men should establish their oral NAD+ response before escalating to IV. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

NAD+ Safety Profile and What to Watch For

NAD+ therapy has a favorable safety profile overall — but understanding the side effect pattern, particularly for IV infusions, helps you navigate a protocol confidently. Buyers searching for nad+ therapy usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Oral NMN and NR supplementation at standard doses (250–1,000mg/day) have demonstrated a reassuring safety profile across multiple independent human trials with durations of up to 12 months. No serious adverse events have been reported at therapeutic doses. Some individuals experience mild GI discomfort, headache, or flushing at higher doses — these typically resolve with dose reduction or splitting doses across the day. IV NAD+ has a more noticeable side effect profile during infusion itself. Common during-infusion effects: mild chest tightness, a sensation of pressure or constriction (not cardiac — it's a vascular response to rapid NAD+ delivery), flushing, nausea, and lightheadedness. These are rate-dependent — they occur primarily when infusion is administered too quickly and resolve when the rate is slowed. A well-run clinic should start with a slow infusion rate (especially for first-time patients) and adjust based on tolerance. The long-term safety record of IV NAD+ is solid based on clinical experience, though large independent controlled trials on adverse events are limited. One area of ongoing research: high-dose NAD+ supplementation's interaction with some cancers, particularly via CD38 and PARP pathways. Men with active malignancy should consult with their oncologist before starting NAD+ therapy. For most healthy men on a supervised longevity protocol, NAD+ therapy has an excellent risk-benefit profile. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: dismissing during-infusion discomfort as fine rather than asking the clinic to slow the infusion rate — pressure and chest tightness during IV NAD+ is almost always a rate issue, not a safety emergency, but it should be managed by slowing the drip. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

How to Access Quality NAD+ Therapy in 2026

Quality matters significantly in NAD+ therapy — particularly for IV protocols — and knowing what to look for in a clinic separates effective protocols from expensive underperformance. Buyers searching for nad+ therapy usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

For oral supplementation, access is straightforward — NMN and NR are widely available supplements. The main quality consideration is sourcing: buy from brands that publish third-party purity testing and have independent research affiliations. For IV NAD+ therapy, clinic selection matters more. Key indicators of quality: pharmaceutical-grade NAD+ sourcing (ask which compounding pharmacy they use and whether it's FDA-registered), physician oversight (not just a wellness technician), infusion rate protocols (slow rates for first-time patients), and intake labs (a quality clinic should want your baseline bloodwork). Most reputable longevity telehealth clinics now offer IV NAD+ as part of a broader longevity protocol alongside TRT, peptides, and other interventions. Standalone IV drip bars offer NAD+ but often without the physician oversight and integrated protocol design of a full longevity clinic — appropriate for occasional infusions but less ideal for a structured protocol. For a full breakdown of current providers offering NAD+ therapy and how they compare, see our best NAD+ IV therapy providers guide. For TRT providers who also offer comprehensive longevity protocols, our provider comparison tool covers the full landscape. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: choosing a clinic based on price or convenience without verifying pharmaceutical-grade NAD+ sourcing — purity and concentration variation in IV NAD+ preparations significantly affects both efficacy and safety. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Internal Resources to Compare Next

Use these pages to validate assumptions before spending. Cross-checking provider model details with treatment-specific pages is the fastest way to reduce preventable cost drift in month two and month three.

Compare Providers Before You Purchase

NAD+ therapy works best as part of a supervised longevity protocol — not a standalone supplement purchase. The clinics below offer physician-supervised NAD+ IV protocols alongside TRT and peptide therapy, with lab-based intake and regular monitoring. Use our comparison tool to find the right fit for your goals and budget.

Disclosure: PeakedLabs may earn a commission from partner links. Editorial scoring and rankings remain independent.

Frequently Asked Questions

What is NAD+ therapy and what does it do?

NAD+ (nicotinamide adenine dinucleotide) therapy attempts to restore declining cellular NAD+ levels through supplementation or IV infusion. NAD+ is a coenzyme essential for cellular energy production (ATP), DNA repair via PARP enzymes, and sirtuin longevity pathway activation. Levels decline approximately 50% by age 60, with downstream effects on energy, metabolism, cognitive function, and recovery. Restoring NAD+ levels supports these pathways and has documented benefits in human clinical trials.

Is IV NAD+ therapy worth the cost?

For men over 45 with documented fatigue, metabolic issues, or slow recovery — and who can afford $150–$350/session after package pricing — IV NAD+ therapy has meaningful evidence behind it and strong clinical response rates. For younger men with no documented metabolic issues, the evidence-to-cost ratio favors starting with oral NMN or NR supplementation at $50–$120/month first. Oral supplementation captures most of the benefit at a fraction of IV costs for most men beyond the loading phase.

What is the difference between NMN and NR?

Both NMN and NR are oral NAD+ precursors that reliably raise cellular NAD+ levels in human trials. NMN enters cells via a specific transporter (Slc12a8) for slightly more direct conversion; NR goes through one additional metabolic step (NMN → NAD+). In practice at matched doses, the outcome difference in human trials is modest. NMN commands a higher price due to David Sinclair lab publicity; NR has a longer independent safety track record and lower cost. Both are effective starting points.

How long does it take to feel the effects of NAD+ therapy?

IV NAD+ infusions often produce noticeable energy and clarity effects during or immediately after infusion. Oral NMN or NR supplementation typically requires 2–6 weeks of consistent use for subjective effects to emerge — cellular NAD+ restoration with oral precursors is gradual. More objective improvements in metabolic markers and fatigue scores are typically measurable at 8–12 weeks of oral supplementation.

Can you take NAD+ supplements with TRT?

Yes — NAD+ and TRT address different biological axes (cellular energy/DNA repair vs. androgenic signaling) and are commonly combined at longevity clinics. Men on TRT who still experience fatigue or cognitive fog often benefit from adding NAD+ therapy, as the residual symptoms may reflect mitochondrial energy deficits rather than testosterone deficiency. See our NAD+ and TRT guide for detail on how these protocols complement each other.

Are there side effects of NAD+ therapy?

Oral NMN and NR at standard doses (250–500mg/day) have an excellent safety profile in human trials — mild GI discomfort in some individuals at higher doses, otherwise minimal. IV NAD+ infusions produce rate-dependent during-infusion effects: chest tightness, flushing, nausea, and lightheadedness. These are managed by slowing the infusion rate and typically resolve within minutes. Serious adverse events from NAD+ therapy are rare. Men with active malignancy should consult their oncologist before starting.

What dose of NMN or NR should I take?

The best-studied human ranges are 250–500mg/day for both NMN and NR. Most clinical trials showing benefits have used doses in this range. Higher doses (750–1,200mg/day NMN) have been studied without serious adverse events but with less evidence of proportional additional benefit. Starting at 250–500mg/day and increasing to 500–1,000mg/day if response is limited is the conservative approach.

Does NAD+ therapy reverse aging?

NAD+ therapy addresses a documented biological hallmark of aging (declining cellular NAD+) and produces measurable improvements in cellular energy metabolism, DNA repair markers, and metabolic function in human trials. Whether this translates to extended human lifespan is a question that current trials are not yet designed to answer definitively. The honest characterization: NAD+ therapy supports important cellular processes that decline with age, with growing human evidence for metabolic and energy benefits — but 'reversal' is ahead of what current evidence shows.

Where can I get NAD+ IV therapy near me?

IV NAD+ is available at longevity-focused telehealth clinics, IV wellness centers, and integrative medicine practices. Quality varies significantly — look for physician oversight, pharmaceutical-grade NAD+ sourcing from an FDA-registered compounding pharmacy, and intake labs. See our best NAD+ IV therapy providers guide for a reviewed list of current providers.

Is NAD+ therapy covered by insurance?

No — IV NAD+ therapy and NMN/NR supplements are not typically covered by standard health insurance as of 2026. They're considered elective longevity interventions rather than treatment for a specific diagnosed condition. Some HSA/FSA accounts may cover NAD+ therapy when prescribed by a physician for a documented condition — check with your plan administrator.